Immuneel Therapeutics: Financial Breakdown
Decoding financial health metrics of Immuneel Therapeutics
Total Revenue₹2.2 Cr-48%Prev. FY
Total Expenses₹56.0 Cr28%Prev. FY
Profit After Tax₹-53.8 Cr-38%Prev. FY
Total Assets₹71.5 Cr-47%Prev. FY
Net Profit Margin-23.9%-162%Prev. FY
FAQs on Financials of Immuneel Therapeutics
No. In FY25, Immuneel Therapeutics reported a net loss of ₹40.5 Cr, so it was not profitable.
Immuneel Therapeutics's revenue grew 341.0% year-on-year, from ₹2.2 Cr in FY24 to ₹9.9 Cr in FY25.
Immuneel Therapeutics's estimated EBITDA for FY25 was ₹-32.9 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY25, Immuneel Therapeutics posted revenue of ₹9.9 Cr (up 341.0% YoY) and a net loss of ₹40.5 Cr. Explore the full financials of Immuneel Therapeutics here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links